Pharmaceutical - North America

Filter

Current filters:

North America

Popular Filters

7066 to 7090 of 7233 results

Pfizer and Bristol-Myers get first approval for blood thinner Eliquis, in EU

23-05-2011

Following a positive recommendation from its drug advisory body (The Pharma Letter March 21), the European…

Bristol-Myers SquibbCardio-vascularEliquisEuropePfizerPharmaceuticalRegulation

German biopharmaceuticals’ growth curbed by drug pricing reforms

23-05-2011

Demand for biopharmaceuticals continued to expand in Germany last year. Turnover in the genetically engineered…

BiotechnologyEuropeMarkets & MarketingPharmaceuticalPricingResearch

Canadian cancer research group spins out three companies

23-05-2011

Canada’s Ontario Institute for Cancer Research (OICR) has announced investments in three new Ontario…

FinancialNorth AmericaOncologyResearch

GAVI commits $100 million to fight meningitis A

23-05-2011

The GAVI Alliance has committed $100 million to help tackle meningitis A in Cameroon, Chad and Nigeria,…

FinancialMenAfriVacPharmaceuticalRest of the WorldVaccines

Fight over user fees underscores bigger questions about US FDA's mission, Burrill report finds

23-05-2011

Industry frustration is growing over a failure to adequately fund the US Food and Drug Administration…

FinancialNorth AmericaPharmaceuticalRegulation

GlaxoSmithKline’s diabetes drug Avandia to be restricted on US market

20-05-2011

As part of a US Food and Drug Administration re-assessment of UK drug giant GlaxoSmithKline’s troubled…

AvandiaDiabetesGlaxoSmithKlineNorth AmericaPharmaceuticalRegulation

Sandoz files for generic of Shire’s Vyvanse; FDA warning

20-05-2011

Ireland-headquartered biopharmaceutical company Shire (LSE: SHP) yesterday revealed that its US subsidiary…

GenericsMarkets & MarketingNeurologicalNorth AmericaNovartisPatentsPharmaceuticalRegulationSandozShireVyvanse

Pfizer Ph II study confirms efficacy of Ablynx' ozoralizumab in RA

20-05-2011

Belgian drug developer Ablynx (Euronext Brussels: ABLX) revealed top-line results from the recently…

AblynxAnti-Arthritics/RheumaticsFinancialozoralizumabPfizerPharmaceuticalResearch

Roche and Evotec terminate Ph II study with NR2B in treatment-resistant depression

20-05-2011

German biotech firm Evotec AG (Xetra: EVT) and Swiss drug major Roche (SIX: ROG) say they have decided…

BiotechnologyEvotecLicensingNeurologicalPharmaceuticalResearchRoche

Pharma distribution in Central Europe in 2011: liberalization of non-pharmacy and on-line sales

20-05-2011

Pharmaceutical distribution has been liberalized further in Central Europe in 2011, with Bulgaria making…

EuropeMarkets & MarketingPharmaceuticalRegulation

Roundup of upcoming cancer drug trials to be presented at ASCO

20-05-2011

A number of leading pharmaceutical companies – include Pfizer, Bayer, Roche and AstraZeneca - have…

AstraZenecaaxitinibBayerMetMAbNexavarolaparibOncologyPfizerPharmaceuticalResearchRoche

FDA advisory panel backs continued use of Abbott’s Trilipix with statins

20-05-2011

The US Food and Drug Administration’s Endocrinologic and Metabolic Drugs Advisory Committee to review…

Abbott LaboratoriesCardio-vascularNorth AmericaPharmaceuticalRegulationTrilipix

Record $3 billion disbursed in 2010 by Global Fund to Fight AIDS

20-05-2011

The Global Fund to Fight AIDS, Tuberculosis and Malaria disbursed a record $3 billion in 2010. This helped…

Anti-viralsFinancialGlobalHealthcarePharmaceuticalTropical diseases

10% of US cancer patients abandoned oral drug therapy, often on cost grounds

20-05-2011

In the USA, 10% of cancer patients failed to fill their initial prescriptions for oral anti-cancer drugs,…

HealthcareNorth AmericaOncologyPharmaceuticalPricing

Nycomed agrees to 9.6 billion euros takeover by Takeda

19-05-2011

Despite just yesterday again saying that it "has not agreed to any such an agreement," this morning Takeda…

Mergers & AcquisitionsNycomedPharmaceuticalTakeda Pharmaceuticals

Global pharma market will see just 3%-6% growth over next five years, reaching $1,100 billion in 2015

19-05-2011

Global spending for medicines will reach nearly $1,100 billion by 2015, reflecting a slowing compound…

GenericsGlobalMarkets & MarketingPatentsPharmaceutical

US cancer drug use and spending to rise sharply by 2013, followed by diabetes and CNS, says Medco

19-05-2011

Expensive new cancer drugs treating increasing numbers of patients could drive cancer drug spending by…

DiabetesMarkets & MarketingNeurologicalNorth AmericaOncologyPharmaceuticalPricing

Astellas’ mirabegron improves key OAB symptoms in Ph III study

19-05-2011

The US subsidiary of Japanese drug major Astellas (TSE: 4503) says that the results of a pivotal Phase…

Astellas PharmaGastro-intestinalsmirabegronPharmaceuticalResearch

Public Citizen says US FDA should immediately pull Eisai and Pfizer’s high-dose Aricept from market

19-05-2011

US consumer watchdog Public Citizen has called for higher doses of Aricept (donepezil), marketed by originator…

AriceptEisaiNeurologicalNorth AmericaPfizerPharmaceuticalRegulation

Amgen says Xgeva first drug to prevent spread of bone cancer in prostate cancer patients

19-05-2011

Amgen (Nasdaq: AMGN), the world’s largest biotech company, has announced primary results of a pivotal…

AmgenBiotechnologyOncologyPharmaceuticalResearchXgeva

Eisai gets Swiss approval for Halaven

19-05-2011

Japanese drug major Eisai (TYO: 4532), says that its Halaven(eribulin) has been approved for use in…

EisaiEuropeHalavenOncologyPharmaceuticalRegulation

Satisfaction with gastric cancer treatment options remains low, GfK study notes

19-05-2011

In just over a month following the US Food and Drug Administration’s approval last fall of Swiss…

HerceptinMarkets & MarketingOncologyPharmaceuticalRoche

7066 to 7090 of 7233 results

Back to top